Zacks Issues Update on their "Outperform" Research Report on Access Pharmaceuticals (OTCBB: ACCP)
Posted by Mike Sweeney on Thu, Aug 19, 2010 @ 12:50 PM
Grand Zeng of Zacks Research issued an update yesterday on their "Outperform" rating on Access Pharmaceuticals (OTCBB: ACCP) with a six month price target of $8.00. ACCP is trading today at $1.95.
Download Zacks' ACCP Update - 8/18/10
Zacks Equity Research combines quantitative models with the insight provided by experienced equity analysts to create superior long-term stock recommendations.
Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining).